N-acetylcysteine for antioxidant therapy : pharmacology and clinical utility

Dodd, Seetal, Dean, Olivia, Copolov, David L., Malhi, Gin S. and Berk, Michael 2008, N-acetylcysteine for antioxidant therapy : pharmacology and clinical utility, Expert opinion on biological therapy, vol. 8, no. 12, pp. 1955-1962, doi: 10.1517/14728220802517901.

Attached Files
Name Description MIMEType Size Downloads

Title N-acetylcysteine for antioxidant therapy : pharmacology and clinical utility
Formatted title N-acetylcysteine for antioxidant therapy : pharmacology and clinical utility
Author(s) Dodd, SeetalORCID iD for Dodd, Seetal orcid.org/0000-0002-7918-4636
Dean, OliviaORCID iD for Dean, Olivia orcid.org/0000-0002-2776-3935
Copolov, David L.
Malhi, Gin S.
Berk, MichaelORCID iD for Berk, Michael orcid.org/0000-0002-5554-6946
Journal name Expert opinion on biological therapy
Volume number 8
Issue number 12
Start page 1955
End page 1962
Total pages 8
Publisher Informa Healthcare
Place of publication London, England
Publication date 2008-12-01
ISSN 1354-3776
Keyword(s) antioxidant
N -acetylcysteine
oxidative stress
Summary Glutathione is an endogenous antioxidant and has a ubiquitous role in many of the body’s defences. Treatment with N -acetylcysteine (NAC) has been shown to increase levels of glutathione. NAC has been proposed as a treatment for several illnesses. Objectives : The efficacy and tolerability of NAC was examined across a range of conditions to evaluate the evidence supporting the use of NAC for each indication. Methods : A literature search was conducted using PubMed. Information was also collected from other online sources including the websites of the Therapeutic Goods Administration of Australia and the FDA. Results : Reports ranged from case studies to clinical trials. There is strong evidence to support the use of NAC for the treatment of paracetamol overdose and emerging evidence suggesting it has utility in psychiatric disorders, particularly schizophrenia and bipolar disorder. NAC is safe and well tolerated when administered orally but has documented risks with intravenous administration.
Language eng
DOI 10.1517/14728220802517901
Field of Research 119999 Medical and Health Sciences not elsewhere classified
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2008, Informa UK
Persistent URL http://hdl.handle.net/10536/DRO/DU:30035480

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 261 times in TR Web of Science
Scopus Citation Count Cited 284 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 932 Abstract Views, 4 File Downloads  -  Detailed Statistics
Created: Tue, 21 Jun 2011, 14:40:14 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.